Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022, 166(1):12-20 | DOI: 10.5507/bp.2021.063

Comparison of remdesivir and favipiravir - the anti-Covid-19 agents mimicking purine RNA constituents

Faiha M. Al-Ardhia, Ladislav Novotnya, Adel Alhunayanb, Naser F. Al-Tannaka
a Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Health Science Center, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait
b Faculty of Medicine, Health Science Center, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait

By December 2019, humanity was challenged by a new infectious respiratory disease named coronavirus disease of 2019 or COVID-19. This is a viral infection based on the presence of the previously non-problematic coronavirus with assigned number 2. This virus causes severe acute respiratory distress and is known now as SARS-CoV2. Since SARS-CoV2 is an RNA virus, remdesivir and favipiravir, both broad-spectrum RNA polymerase inhibitors, were repurposed for treating COVID-19 patients. Remdesivir and favipiravir are antimetabolites, and they are structurally related to the naturally occurring structural elements of RNA. Both agents are prodrugs and must be activated intracellularly to exert their effects through numerous and different mechanisms of action. Efforts have been exerted to determine their efficacy and safety against COVID-19 through clinical trials. Clinical trials have shown an association of remdesivir with increased frequency of adverse effects (in comparison to favipiravir). Nevertheless, the data obtained with remdesivir resulted in its approval by the FDA on the 22nd of October 2020 for COVID-19 treatment. At present, remdesivir is being recommended by several treatment guidelines for the treatment of COVID-19 patients. The evidence in favor of favipiravir is compromised by the small number and low-quality of trials conducted. Favipiravir has shown various benefits when administered in mild and moderate cases of COVID-19, while remdesivir was more beneficial in more severe cases of the disease. Since the two agents are suitable for different groups of patients, both drugs can play a significant role in fighting this pandemic. The goal of this work is to summarize the information available on two antimetabolites - remdesivir and favipiravir - and to compare clinical experience obtained so far with these two agents in COVID-19 patients.

Keywords: remdesivir, favipiravir, Covid-19, antimetabolites, RNA-polymerase inhibitors, respiratory syndrome

Received: July 16, 2021; Revised: October 26, 2021; Accepted: November 2, 2021; Prepublished online: November 15, 2021; Published: March 1, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Al-Ardhi, F.M., Novotny, L., Alhunayan, A., & Al-Tannak, N.F. (2022). Comparison of remdesivir and favipiravir - the anti-Covid-19 agents mimicking purine RNA constituents. Biomedical papers, 166(1), 12-20. doi: 10.5507/bp.2021.063
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. World Health Organization. Timeline: WHO's COVID-19 response. 2020 [accessed 2021 September 12]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline.
    2. Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, Singh KP, Chaicumpa W, Bonilla-Aldana DK, Rodriguez-Morales AJ. Coronavirus Disease 2019-COVID-19. Clin Microbiol Rev 2020;33:e00028-20. doi: 10.1128/cmr.00028-20 Go to original source... Go to PubMed...
    3. Kadam S B, Sukhramani GS, Bishnoi P, Pable AA, Barvkar VT. SARS-CoV-2, the pandemic coronavirus: Molecular and structural insights. J Basic Microbiol 2021;61:180-202. doi: 10.1002/jobm.202000537 Go to original source... Go to PubMed...
    4. Ni W, Yang X, Yang D, Bao J, Li R, Xiao Y, Hou C, Wang H, Liu J, Yang D, Xu Y, Cao Z, Gao Z. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care 2020;24:422. doi: 10.1186/s13054-020-03120-0 Go to original source... Go to PubMed...
    5. Delikhoon M, Guzman MI, Nabizadeh R, Norouzian Baghani A. Modes of transmission of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) and factors influencing on the airborne transmission: A review. Int J Environ Res Public Health 2021;18:395. doi: 10.3390/ijerph18020395 Go to original source... Go to PubMed...
    6. National Institutes of Health. COVID-19 Treatment Guidelines. 2021 [accessed 2021 September 12]. Available from: https://www.covid19treatmentguidelines.nih.gov/
    7. Jordheim LP, Durantel D, Zoulim F, Dumontet C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nature Rev Drug Discovery 2013;12:447-464. doi: 10.1038/nrd4010 Go to original source... Go to PubMed...
    8. Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, Hall MD. Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Central Science 2020;6:672-83. doi: 10.1021/acscentsci.0c00489 Go to original source... Go to PubMed...
    9. Yates MK, Seley-Radtke KL. The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold. Antiviral Res 2018;154:66-86. doi: 10.1016/j.antiviral.2018.04.004 Go to original source... Go to PubMed...
    10. Jordan PC, Stevens SK, Deval J. Nucleosides for the treatment of respiratory RNA virus infections. Antiviral Chem Chemotherapy 2018;26:204020661876448. doi: 10.1177/2040206618764483 Go to original source... Go to PubMed...
    11. Vardanyan R, Hruby V. Chapter 34 - Antiviral Drugs. In Vardanyan R, Hruby V., editors. Synthesis of Best-Seller Drugs, Elsevier (Academic Press imprint) 2016, pp. 687-736. doi: 10.1016/b978-0-12-411492-0.00034-1 Go to original source...
    12. Yates MK, Seley-Radtke KL. The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold. Antiviral Res 2019:162:5-21. doi: 10.1016/j.antiviral.2018.11.016 Go to original source... Go to PubMed...
    13. Umar Y. Theoretical studies of the rotational and tautomeric states, electronic and spectroscopic properties of favipiravir and its structural analogues: a potential drug for the treatment of COVID-19. J Taibah University for Science 2020;14:1613-25. doi: 10.1080/16583655.2020.1848982 Go to original source...
    14. Naesens L, Guddat LW, Keough DT, Van Kuilenburg A B, Meijer J, Vande Voorde J, Balzarini J. Role of human hypoxanthine-guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir). Mol Pharmacol 2013;84:615-29. doi: 10.1124/mol.113.087247 Go to original source... Go to PubMed...
    15. Liu P, Sharon A, Chu CK. Fluorinated nucleosides: Synthesis and biological implication. J Fluorine Chem 2008;129:743-66. doi: 10.1016/j.jfluchem.2008.06.007 Go to original source... Go to PubMed...
    16. Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K. Mechanism of action of T-705 against Influenza Virus. Antimicrobial Agents Chemother 2005;49:981-86. doi: 0.1128/aac.49.3.981-986.2005 Go to original source... Go to PubMed...
    17. Shannon A, Le NT-T, Selisko B, Eydoux C, Alvarez K, Guillemot J-C, Decroly E, Peersen O, Ferron F, Canard B. Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 exonuclease active-sites. Antiviral Res 2020;178:104793. doi: 10.1016/j.antiviral.2020.104793 Go to original source... Go to PubMed...
    18. Shannon A, Selisko B, Le N-T-T, Huchting J, Touret F, Piorkowski G, Fattorini V, Ferron F, Decroly E, Meier C, Coutard B, Peersen O, Canard B. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat Commun 2020;11:4682. doi: 10.1038/s41467-020-18463-z Go to original source... Go to PubMed...
    19. Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP, Götte M. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem 2020;295:6785-97. doi: 10.1074/jbc.ra120.013679 Go to original source... Go to PubMed...
    20. Tchesnokov EP, Gordon C J, Woolner E, Kocinkova D, Perry JK, Feng JY, Porter DP, Götte M. Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action. J Biol Chem 2020;295:16156-65. doi: 10.1074/jbc.ac120.015720 Go to original source... Go to PubMed...
    21. Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res 2018;153:85-94. doi: 10.1016/j.antiviral.2018.03.003 Go to original source... Go to PubMed...
    22. Search of: Remdesivir | Covid19 - List results - ClinicalTrials.gov. ClinicalTrials.gov. [accessed 2021 June 10]. Available from: https://clinicaltrials.gov/ct2/results?cond=Covid19&term=remdesivir&cntry=&state=&city=&dist=&Search=Search
    23. The search of Favipiravir | Covid19 - List results - ClinicalTrials.gov. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results?cond=Covid19&term=favipiravir&cntry=&state=&city=&dist=&Search=Search
    24. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh M, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med 2020;383:1813-26. doi: 10.1056/nejmoa2007764 Go to original source... Go to PubMed...
    25. Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, Spinner CD, Galli M, Ahn M-Y, Nahass RG, Chen Y-S, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wei X, Gaggar A, Brainard DM, Towner WJ, Muñoz j, Mullane KM, Marty FM, Tashima KT, Diaz G, Subramanian A. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med 2020;383:1827-37. doi: 10.1056/NEJMoa2015301 Go to original source... Go to PubMed...
    26. Pan H, Peto R, Henao-Restrepo A-M, Preziosi M-P, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernández García C, Kieny M-P, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, García PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portolés A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H, Røttingen J-A, Swaminathan S. Repurposed antiviral drugs for Covid-19 - Interim WHO Solidarity Trial results. N Engl J Med 2021;384:497-511. doi: 10.1056/NEJMoa2023184 Go to original source... Go to PubMed...
    27. Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wang H, Gaggar A, Brainard DM, McPhail MJ, Bhagani S, Ahn MY, Sanyal AJ, Huhn G, Marty FM. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19. JAMA 2020;324:1048-57. doi: 10.1001/jama.2020.16349 Go to original source... Go to PubMed...
    28. Doi Y, Kondo M, Ando M, Kuwatsuka Y, Ishihara T. Favipiravir Observational Study Interim Report 3. Fujita Health University, 2021, [accessed 2021 September 12]. Available from: https://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_favip_2100419_eng.pdf
    29. Udwadia ZF, Singh P, Barkate H, Patil S, Rangwala S, Pendse A, Kadam J, Wu W, Caracta CF, Tandon M. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis 2021;103:62-71. doi: 10.1016/j.ijid.2020.11.142 Go to original source... Go to PubMed...
    30. Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, Mutoh Y, Homma Y, Terada M, Ogawa T, Kashizaki F, Yokoyama T, Koba H, Kasahara H, Yokota K, Kato H, Yoshida J, Kita T, Kato Y, Kamio T, Kodama N, Uchida Y, Ikeda N, Shinoda M, Nakagawa A, Nakatsumi H, Horiguchi T, Iwata M, Matsuyama A, Banno S, Koseki T, Teramachi M, Miyata M, Tajima S, Maeki T, Nakayama E, Taniguchi S, Lim CK, Saijo M, Imai T, Yoshida H, Kabata D, Shintani A, Yuzawa Y, Kondo M. A prospective, randomized, open-label trial of early versus late Favipiravir therapy in hospitalized patients with COVID-19. Antimicrob Agents Chemother 2020;64:e01897-20. doi: 10.1128/AAC.01897-20 Go to original source... Go to PubMed...
    31. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang Y, Shen C, Li X, Peng l, Huang D, Zhang J, Zhang S, Wang F, Liu J, Chen L, Chen S, Wang Z, Zhang Z, Cao R, Zhong W, Liu Y, Liu L. Experimental treatment with Favipiravir for COVID-19: An open-label control study. Engineering (Beijing) 2020;6:1192-198. doi: 10.1016/j.eng.2020.03.007 Go to original source... Go to PubMed...
    32. Fan Q, Zhang B, Ma J, Zhang S. Safety profile of the antiviral drug remdesivir: An update. Biomed & Pharmacotherapy 2020;130:110532. doi: 10.1016/j.biopha.2020.110532 Go to original source... Go to PubMed...
    33. Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, Patil S, Barkate H. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis 2021;102:501-8. doi: 10.1016/j.ijid.2020.10.069 Go to original source... Go to PubMed...
    34. Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India 2020;76(4):370-76. doi: 10.1016/j.mjafi.2020.08.004 Go to original source... Go to PubMed...
    35. US Food and Drug Administration. FDA's approval of Veklury (remdesivir) for the treatment of COVID-19, (2020, October 22), [accessed 2021 September 12]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fdas-approval-veklury-remdesivir-treatment-covid-19-science-safety-and-effectiveness
    36. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, Edwards KM, Gandhi R, Gallagher J, Muller WJ, O'Horo JC, Shoham S, Murad MH, Mustafa RA, Sultan S, Falck-Ytter Y. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Infectious Diseases Society of America, 2021. [accessed 2021 September 13]. Available from: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ Go to original source... Go to PubMed...
    37. Takuya A, Mugen U, Norio O, Yasuyuki K, Akihiko K, Satoshi K, Toru K, Masayuki S, Koichi T, Shu H, Ryota H, Jiro F, Hiroshi F, Hiroshi M, Masaya Y, Akihito U. (2020). Clinical management of patients with COVID-19: A guide for front-line healthcare workers (Version 2.1). In Ministry of Health, Labour and Welfare of Japan. https://www.mhlw.go.jp/content/000646531.pdf
    38. Covid-19 Response Committee. Guidelines on clinical practice, diagnosis, treatment, and prevention of healthcare-associated infection for COVID-19. Department of Medical Services, Ministry of Public Health, Thailand, 2021 May 6. https://ddc.moph.go.th/viralpneumonia/eng/file/guidelines/g_CPG_06may21.pdf
    39. Ministry of Health, Saudi Arabia, 2021 May 19. Saudi MoH Protocol for Patients Suspected of/Confirmed with COVID-19: Supportive care and antiviral treatment of suspected or confirmed COVID-19 infection (Version 2.9). [accessed 2021 September 12]. Available from: https://www.moh.gov.sa/en/Ministry/MediaCenter/Publications/Pages/covid19.aspx#
    40. Al-Ahmad M, Al-Rasheed M, Alhelal B, Alghareeb H, Alsayegh A, Alhassawi A, Al-Fares AA, Almajed A, Alhajeri H, Alazemi S, Bulbanat B, Al-Mazeedi N, Alroughani R, Alzafiri A, Al-Ozairi E, Alenezi M, Alkandari A, Abdullah AA, Altourah L. Management of COVID-19 in Adults: Kuwait Adult Task Force Recommendation (1st ed.). Kuwait Ministry of Health. A clinical trial evaluating the efficacy and safety of Favipiravir in moderate to severe COVID-19 patients. (n.d.). ClinicalTrials.gov. Retrieved June 28, 2021, from https://clinicaltrials.gov/ct2/show/NCT04529499
    41. Dr. Reddy's Laboratories Ltd., 27 January 2021. Dr. Reddy's and GRA announce Avigan Pivotal Studies Update Study for hospitalized moderate to severe cases in Kuwait terminated while study for out-patient mild to moderate cases continues in North America. https://www.drreddys.com/media/928938/2021-01-avigan-trial-update_v1.pdf
    42. Remdesivir. Pubchem.ncbi.nlm.nih.gov, 2021, [accessed 2021 September 12]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Remdesivir.
    43. Favipiravir. Pubchem.ncbi.nlm.nih.gov, 2021, [accessed 2021 September 12]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/492405

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content